Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform
…
0,479€
-23,43%
Echtzeit-Aktienkurs Cidara Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Cidara Therapeutics Inc. Aktie
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
Cidara Therapeutics announces reverse stock split By Investing.com
Cidara Therapeutics announces reverse stock split…
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company…
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company…
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a…
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host…
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies…
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
SAN DIEGO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced REZZAYO (rezafungin acetate)…
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time Preclinical data on dual CD73/PD-1 targeting…
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on…
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
SAN DIEGO and CAMBRIDGE, England, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its…
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary…
Insiderhandel: CHIEF SCIENTIFIC OFFICER kauft Aktien von Cidara Therapeutics im Wert von 9.700$
Tari, Leslie - Vorstand - Tag der Transaktion: 2023-08-14...…
Cidara Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed lower by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their…
Insiderhandel: President & CEO kauft Aktien von Cidara Therapeutics im Wert von 47.885$
Stein, Jeffrey - Vorstand - Tag der Transaktion: 2023-08-08...…
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -75% and 46.90%, respectively, for the quarter ended June 2023. Do…
Cidara Therapeutics GAAP EPS of -$0.14 misses by $0.01, revenue of $7.61M misses by $3.94M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing immunotherapeutics…
Form 10-Q Cidara Therapeutics, For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara antifungal drug Rezzayo launched in US by partner Melinta
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara says J&J development deal for CD388 remains intact
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting…
Cidara Therapeutics joins Russell Microcap
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Cidara Therapeutics, For: Jun 22
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara gains as FDA grants fast track status for flu candidate
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Gets FDA Fast-Track for Flu Prevention Drug
Cidara Gets FDA Fast-Track for Flu Prevention Drug...…
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting…
Cidara Therapeutics GAAP EPS of $0.03 beats by $0.07, revenue of $25.99M beats by $7.31M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting…
Form 10-Q Cidara Therapeutics, For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference
– Oral presentations demonstrate positive preclinical data highlighting CD388s activity against influenza A and B – – Oral presentations demonstrate…
Cidara earns $20M milestone payment on FDA nod for antifungal
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Therapeutics Gets $20M Milestone Payment for Rezzayo From Melinta
Cidara Therapeutics Gets $20M Milestone Payment for Rezzayo From Melinta...…
Are Options Traders Betting on a Big Move in Cidara (CDTX) Stock?
Investors need to pay close attention to Cidara (CDTX) stock based on the movements in the options market lately....…
Cidara Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting…
Cidara Therapeutics And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by around 200 points on Monday. When insiders purchase or sell shares, it indicates their…
Insiderhandel: President & CEO kauft Aktien von Cidara Therapeutics im Wert von 51.855$
Stein, Jeffrey - Vorstand - Tag der Transaktion: 2023-03-27...…
Dermata, GH Research top healthcare gainers; BridgeBio, Cidara among losers
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara off 27% despite FDA nod amid selloff in antifungal space
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
ZyVersa, Aziyo top healthcare gainers; Cidara, Protagenic among losers
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Therapeutics Shares Dive 20% Despite Improved 4Q Results
Cidara Therapeutics Shares Dive 20% Despite Improved 4Q Results...…
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do…
Cidara Therapeutics GAAP EPS of -$0.19 misses by $0.04, revenue of $10.22M misses by $0.35M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting…
Form 8-K Cidara Therapeutics, For: Mar 23
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara stock dips amid FDA approval of antifungal drug Rezzayo
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cidara Therapeutics Down 3% After Hours Following FDA Approval
Cidara Therapeutics Down 3% After Hours Following FDA Approval...…